Wu Shizheng, Hao Guisheng, Zhang Shukun, Jiang Dongmei, Wuren Tana, Luo Junming
Department of Neurology, Qinghai Provincial People's Hospital, Xining, Qinghai 810007, P.R. China.
Department of Pathology, Qinghai Provincial People's Hospital, Xining, Qinghai 810007, P.R. China.
Mol Med Rep. 2016 Sep;14(3):2497-502. doi: 10.3892/mmr.2016.5555. Epub 2016 Jul 27.
The aim of the present study was to examine cerebral vasoconstriction in patients with chronic high altitude disease [cerebrovascular reactivity (CVR)], and to evaluate differences in alterations of brain vascular contractile reactivity of chronic mountain sickness (CMS) patients and healthy controls. Alterations of endothelin (ET) and its receptor, as well as endothelial nitric oxide synthase (eNOS) levels in the plasma were examined to determine the cerebral reservation capacities in CMS patients. Transcranial Doppler ultrasound and carbon dioxide analysis methods were used to detect the CVR variances. At the same time, enzyme‑linked immunosorbent assay approaches were utilized to detect the ET and ET B receptor and the eNOS levels in serum of the CMS patients and healthy controls. CVR and CVRI levels in CMS patients were lower than those of the healthy control subjects and the difference was statistically significant (P<0.05). By contrast, eNOS and ET‑1 levels were not statistically significant for CMS and healthy controls (P>0.05). However, the ET receptor concentration level was higher in CMS than the healthy controls. Thus, ET‑1 may not be a direct etiological variation but may play compensatory roles in CMS patients. The results of the study may provide scientific clues for the prevention and treatment of CMS with higher blood coagulation states of cerebral infarction in patients with chronic high altitude disease.
本研究的目的是检测慢性高原病患者的脑血管收缩情况[脑血管反应性(CVR)],并评估慢性高原病(CMS)患者与健康对照者脑血管收缩反应性改变的差异。检测血浆中内皮素(ET)及其受体以及内皮型一氧化氮合酶(eNOS)水平的变化,以确定CMS患者的脑储备能力。采用经颅多普勒超声和二氧化碳分析方法检测CVR变化。同时,利用酶联免疫吸附测定法检测CMS患者和健康对照者血清中的ET、ET B受体和eNOS水平。CMS患者的CVR和CVRI水平低于健康对照者,差异有统计学意义(P<0.05)。相比之下,CMS患者和健康对照者的eNOS和ET-1水平无统计学意义(P>0.05)。然而,CMS患者的ET受体浓度水平高于健康对照者。因此,ET-1可能不是直接的病因变异,但可能在CMS患者中起代偿作用。该研究结果可能为慢性高原病患者高凝血状态脑梗死的CMS防治提供科学线索。